Results 21 to 30 of about 328 (133)

Las Salamandras [PDF]

open access: yes, 1974
[No ...
Rivera, Tomás,, Rivera, Tomás
core   +1 more source

Aforismo II - Salamandras Azuis

open access: yes, 2021
Segunda faixa do Ep.
Franco, Edgar
core   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul   +13 more
wiley   +1 more source

The complete mitochondrial genome of Salamandra salamandra (Amphibia: Urodela: Salamandridae) [PDF]

open access: yesMitochondrial DNA Part B, 2016
The complete mitochondrial genome of Salamandra salamandra was reconstructed using bycatch sequences from an RNAseq library generated from muscle tissue. This study shows the potential of using data originally produced for transcriptome assembly to additionally generate complete mitochondrial genomes. The resulting mitogenome was circular, consisted of
Kevin P. Mulder   +3 more
openaire   +5 more sources

Lista de anfibios y reptiles del departamento del Tolima, Colombia

open access: yesBiota Colombiana, 2010
Se construyó el listado taxonómico de especies de anfibios y reptiles del departamento del Tolima, Colombia, con base en la revisión extensa de literatura e información de colecciones biológicas.
Julián Llano-Mejía   +2 more
doaj   +8 more sources

A Tale of Appendages: Investigating Limb and Tail Variation in Salamanders

open access: yesIntegrative Zoology, EarlyView.
We analyzed limb and tail proportions in 44% of known salamander species using a phylogenetic comparative approach. Our results revealed significant variation among families and ecological groups, with aquatic species showing longer limbs and basal lineages having shorter tails.
Giacomo Rosa   +4 more
wiley   +1 more source

Filogenia molecular y revisión taxonómica de las salamandras Bolitoglossa altamazonica y B. peruviana (Caudata: Plethodontidae) de Perú [PDF]

open access: yes, 2021
En este estudio, se examinan las relaciones filogenéticas entre las salamandras del género Bolitoglossa (Eladinea) distribuidas en la cuenca Amazónica del norte de Perú y sur de Ecuador, y se evalúa la diversidad de especies en base a los análisis ...
Cusi Martinez, Juan Carlos
core  

Replace, reduce, refine: A review of animal use in Batrachochytrium salamandrivorans research

open access: yesConservation Science and Practice, EarlyView.
Abstract Animal experimentation is common in wildlife disease research. Understanding the impact of this often‐lethal approach is therefore a critical line of inquiry at the intersection of animal welfare and conservation biology. The discovery of the pathogenic salamander chytrid fungus Batrachochytrium salamandrivorans (Bsal) in 2013 ignited a large ...
Alexandra Boren   +2 more
wiley   +1 more source

Melanism in salamanders: effects of insularity, sex and size on dorsal colouration in Salamandra salamandra

open access: yesJournal of Zoology, EarlyView.
In this study we tested the effects of insularity on amphibian colouration using the fire salamander as a model system. Although increased melanism was not a consistent pattern across all islands, salamanders from one island exhibited higher proportions of black pigmentation than mainland populations, while insular populations overall showed reduced ...
L. Alarcón‐Ríos   +2 more
wiley   +1 more source

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6022-6033, July 2026.
ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy